Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00474136
Recruitment Status : Completed
First Posted : May 16, 2007
Last Update Posted : January 4, 2008
Sponsor:
Information provided by:
Javelin Pharmaceuticals

Brief Summary:
The purpose of this study is to assess the pharmacokinetic parameters of intravenous diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved reference product.

Condition or disease Intervention/treatment Phase
Healthy Drug: Intravenous diclofenac sodium (DIC075V) 18.75 mg Drug: Intravenous diclofenac sodium (DIC075V) 37.5 mg Drug: Oral diclofenac potassium 50 mg Phase 1

Detailed Description:
This study is an open-label, three-treatment, six sequence, three-period, single center crossover study to evaluate the pharmacokinetics of intravenous diclofenac sodium DIC075V (18.75 mg and 37.5 mg) versus oral diclofenac potassium (Cataflam® 50 mg) in healthy adult volunteers following single- and multiple-dose administration. Each treatment sequence received 1 dose every 6 hours (for a total of 4 doses per treatment sequence) with a 48-hour washout period between treatment sequences.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Randomized, Single Center Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses) Versus Oral Diclofenac Potassium in Healthy Adult Volunteers Following Single- and Multiple-Dose Administration
Study Start Date : March 2007
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007


Arm Intervention/treatment
Experimental: 1 Drug: Intravenous diclofenac sodium (DIC075V) 18.75 mg
DIC075V 18.75 mg

Experimental: 2 Drug: Intravenous diclofenac sodium (DIC075V) 37.5 mg
DIC075V 37.5 mg

Active Comparator: 3 Drug: Oral diclofenac potassium 50 mg
Oral diclofenac potassium 50 mg
Other Name: Cataflam




Primary Outcome Measures :
  1. To assess the pharmacokinetic parameters of intravenous diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved reference product. [ Time Frame: Several time points over 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers between 18 and 55 years of age.

Exclusion Criteria:

  • Smoked or used tobacco or nicotine products in the past six months or expects to during the study.
  • Known allergy or hypersensitivity to diclofenac, aspirin, or other NSAIDs.
  • History of previous and/or present peptic ulceration, GI bleeding or any bleeding diathesis, positive for hepatitis B or hepatitis C or for HIV antibodies, or history of asthma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00474136


Locations
Layout table for location information
United States, Maryland
PAREXEL International
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Javelin Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Terri Lunsford, MD Parexel

Layout table for additonal information
Responsible Party: Amy Cohen, Javelin Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00474136     History of Changes
Other Study ID Numbers: DFC-PK-006
First Posted: May 16, 2007    Key Record Dates
Last Update Posted: January 4, 2008
Last Verified: December 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Diclofenac
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action